

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.
06/823+856	01/29/86	TOTVOLA	Þ	FM18-566-F83
L				

PARMSTRONG: NIKAIDO: MARMELSTEIM & KUBOVCIP STE: 912: 1725 K ST.: N. W. WASHINGTON: DC 20006

EXAMINER CHANGEN				
7				
PAPER NUMBER				
<_				

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Tesponsive to communication filed on 5/20/16. A shortened statutory period for response to this action is set to expire 3 month(s), days from the statutory period for response to this action is set to expire 3.	This action is made final.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.	C. 133
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: 1. Notice of References Cited by Examiner, PTO-892. 2. Notice re Patent Draw 3. Notice of Art Cited by Applicant, PTO-1449 4. Notice of informal Part 5. Information on How to Effect Drawing Changes, PTO-1474 6.	tent Application, Form PTO-152
Part II SUMMARY OF ACTION	
1. \(\sims\) \(\frac{19-20+23-26}{\}\)	are pending in the application.
Of the above, claims	are withdrawn from consideration.
2. Claims	have been cancelled.
3. Claims	are allowed.
4. [Voctains 9, 19-20 + 23-26;	are rejected.
5 Claims	are objected to.
6. Claimsare subject	to restriction or election requirement.
7. This application has been filed with informal drawings which are acceptable for examination purp matter is indicated.	oses until such time as allowable subject
8. Allowable subject matter having been indicated, formal drawings are required in response to this	Office action.
9. [_] The corrected or substitute drawings have been received on These di These di	rawings are [] acceptable;
10. [] The [] proposed drawing correction and/or the [] proposed additional or substitute sheet(s) of has (have) been [] approved by the examiner. [] disapproved by the examiner (see explanation)	
11. The proposed drawing correction, filed	sibility to ensure that the drawings are
12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has [4]	been received [] not been received
been filed in parent application, serial no. 497, 813; filed on 5	·/
 Since this application appears to be in condition for allowance except for formal matters, prosect accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. 	mon no to the ments is crosed in
14. Other	

EXAMINER'S ACTION

PTOL-326 (Rev. 7 - 82)

-2-

Serial No. 823,856

Art Unit 123

The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 19-20 and 23-24 are rejected under 35
U.S.C. 103 as being unpatentable over Allen et al. The reference compounds differs from the claimed compounds only by an ethylene group and both compounds are estrogen antagonists. The claimed compound is structural obvious over the reference compound.

The two declarations submitted in the parent applications can only obviate the rejection of the claims with respect to the compound wherein R is Chloro.

Evidence of unobvious properties of the claimed compound wherein R is bromo over the reference compound of example 4 would be persuasive of the patentability of the claims under sections 102 and 103.

823,856 -3-

Art Unit 123

Serial No.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C.

112, first paragraph, as failing to adequately teach how
to make and use the invention.

The specification fails to teach what proportions of the "mixture' recited in the claims are useful.

Each of the three responses recited in claim 19 is dosage and species dependent and the specification has not taught the effective amount that can produce each of the three responses. Moreover, not all the claimed compounds can produce all three responses and the specification has not taught which compound can produce which response.

Claim 9, 19-20 and 23-26 are rejected under 35 U.S.C. 112, first paragraph, for the reasons set forth in the above objection to the specification. Moreover, the anti-tumor effective amount of active ingredients should be recited in claim 23 and "mixtures" should be deleted from claim 24.

The cited references are of record in the parent

Serial No. 823,856

Art Unit 123

This is a continuation of applicant's earlier application S.N. 497,813. All rejected claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds or art of record in the next Office action if they had been entered in the earlier application.

Accordingly, THIS ACTION IS MADE FINAL even though it is a first action in this case. See MPEP 706.07(b).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). The practice of automatically extending the shortened statutory period an additional month upon the filing of a timely first response to a final rejection has been discontinued by the Office. See 1021 TMOG 35.

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 CFR 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

Chan/kl

703/557-3920

10-11-86

NICKY CHAN PRIMARY EXAMINER ART UNIT 123

/ hickfela.